Q-omics provides the consensus-scored ADCY8 profile across patient tissues and cancer cell-line models. ADCY8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ADCY8 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ADCY8 RNA expression shows 8,993 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, THCA, and TGCT as cancer lineages where ADCY8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADCY8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADCY8 survival associations across molecular data types. ADCY8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADCY8 RNA expression–survival associations across cancer types. High ADCY8 expression shows unfavorable associations in UCEC, KICH, BRCA and DLBC, but favorable associations in SKCM and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for ADCY8 RNA expression.
This table summarizes ADCY8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ADCY8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADCY8 shows lower tumor expression in LUAD, UCEC, LUSC and KICH and higher tumor expression in THCA and KIRC. The THCA box plot shows higher ADCY8 RNA expression in tumor versus normal tissue (log2 FC = +2.615, t-test p < 0.001).
This table shows molecular features associated with ADCY8 in patient tissues and cancer cell lines. In patient samples, ADCY8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ADCY8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
